Al-Gareeb Ali, Gorial Faiq, Mahmood Ahmed
Department of Clinical Pharmacology, Mustansiriyah University College of Medicine, Baghdad, Iraq.
Department of Rhumatology, Baghdad University, College of Medicine, Baghdad, Iraq.
Arch Rheumatol. 2019 Jan 23;34(4):426-433. doi: 10.5606/ArchRheumatol.2019.7100. eCollection 2019 Dec.
This study aims to evaluate the anti-arthritic effect of orally administered niclosamide (NCL) on collagen-induced arthritis (CIA) in rats.
The study included 35 Sprague Dawley rats (age range, 3 to 4 months; average weight, 100±10 g) of which seven were used as a negative control group (group A) whereas 28, in which arthritis was induced by injection of collagen type II emulsified by incomplete Freund's adjuvant and which were considered as CIA rats, were randomly divided equally into four groups and treated for 28 days with: normal saline (group B), low-dose NCL (group C), high-dose NCL (group D), and diclofenac sodium (group E). Body weight, arthritis index, ankle swelling, and footpad thickness were monitored before and after treatment in all groups. At the end of the treatment period, serum levels of tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), and IL-6 were measured together with a collection of articular synovial tissue to evaluate the pathological changes.
After four weeks of treatment period, a high dose of orally administered NCL significantly reduced the arthritis index, footpad thickness, and ankle swelling. Significantly decreased serum levels of inflammatory biomarkers including TNF-α, IL-1β, and IL-6 were observed in rats treated with high-dose oral NCL or intramuscular injection of diclofenac sodium, compared with groups B and C. Histopathological examination revealed that a high dose of NCL significantly reduced the infiltration of inflammatory cells, synovial hyperplasia, and bone and cartilage destruction.
Niclosamide can effectively decrease the clinical scores, joint swelling, inflammatory markers, and pathological changes in arthritic rats.
本研究旨在评估口服氯硝柳胺(NCL)对大鼠胶原诱导性关节炎(CIA)的抗关节炎作用。
本研究纳入35只Sprague Dawley大鼠(年龄范围为3至4个月;平均体重为100±10克),其中7只作为阴性对照组(A组),而28只通过注射不完全弗氏佐剂乳化的II型胶原诱导关节炎,被视为CIA大鼠,随机平均分为四组,并分别用以下药物治疗28天:生理盐水(B组)、低剂量NCL(C组)、高剂量NCL(D组)和双氯芬酸钠(E组)。在所有组治疗前后监测体重、关节炎指数、踝关节肿胀和足垫厚度。在治疗期结束时,测量血清肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)和IL-6水平,并收集关节滑膜组织以评估病理变化。
治疗四周后,高剂量口服NCL显著降低了关节炎指数、足垫厚度和踝关节肿胀。与B组和C组相比,高剂量口服NCL或肌肉注射双氯芬酸钠治疗的大鼠血清中炎症生物标志物TNF-α、IL-1β和IL-6水平显著降低。组织病理学检查显示,高剂量NCL显著减少了炎症细胞浸润、滑膜增生以及骨和软骨破坏。
氯硝柳胺可有效降低关节炎大鼠的临床评分、关节肿胀、炎症标志物和病理变化。